T. Rowe Price Associates
NMRA icon

T. Rowe Price Associates’s Neumora Therapeutics NMRA Stock Holding History

T. Rowe Price Associates’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,548
Closed -$33K – 3120
2025
Q1 		$33K Hold
32,548
– – ﹤0.01% 2976
2024
Q4 		$346K Sell
32,548
-592,930
-95% -$7.11M ﹤0.01% 2446
2024
Q3 		$8.26M Sell
625,478
-44,008
-7% -$513K ﹤0.01% 1177
2024
Q2 		$6.58M Sell
669,486
-83,438
-11% -$863K ﹤0.01% 1174
2024
Q1 		$10.4M Buy
+752,924
New +$12.2M ﹤0.01% 1102

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates's NMRA Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 32,548 shares — an estimated $33K sold.

T. Rowe Price Associates first reported a position in NMRA in Q1 2024 and held it in 5 quarters. The position peaked at $10.4M in Q1 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 32,548 Neumora Therapeutics shares in Q2 2025, an estimated $33K.
  • T. Rowe Price Associates first reported a position in Neumora Therapeutics in Q1 2024 and held it in 5 quarters.
  • T. Rowe Price Associates's Neumora Therapeutics position peaked at $10.4M in Q1 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.